It also benefits those with a family history of breast, uterine, or ovarian cancer, as well as men with prostate cancer histories
Our providers are trained to assess your risk and prescribe responsibly
Key clinical wins : In 2024, Lilly announced new clinical trial results (e.g., further cardiovascular outcome benefits with tirzepatide), which have bolstered prescriber confidence
GLP-1 infusion increases natriuresis by reducing tubular sodium reabsorption and reduces hyperfiltration in obese subjects.50 Chronic treatment with arGLP-1 in patients with DM2 has shown no effect on measured GFR and effective renal plasma flow in the fasting or postprandial state, however it maintains its natriuretic effect.51 GLP-1 and its agonists induce natriuresis by inhibition of the Na+/H + exchanger type 3 in the proximal tubule, although interactions with the renin, insulin, or glucagon system cannot be excluded5254 because they reduce circulating levels of RAS components51,5355 (Fig
Alternatives in Class At a glance Brand Vyvanse (30-day supply) / $350 to $450 cash price Generic lisdexamfetamine (30-day supply) / $30 to $80 cash price (since August 2023) Generic mixed amphetamine salts XR / $15 to $50 per month Generic methylphenidate ER / $20 to $45 per month FDA-approved indications / ADHD (ages 6+) and binge eating disorder (adults) Duration of action / 12 to 13 hours in controlled trials DEA schedule / Schedule II controlled substance Prodrug conversion / Lisdexamfetamine is cleaved to d-amphetamine in red blood cells Patent expiration / August 2023 (first generics launched) Insurance tier / Tier 2 to 3 for generics
( C ) Insulin and glucagon colocalization in the islet
